An eight-year clinic experience with clozapine use in a Parkinson's disease clinic setting.
<h4>Background</h4>To examine our eight year clinic-based experience in a Parkinson's disease expert clinical care center using clozapine as a treatment for refractory psychosis in Parkinson's disease (PD).<h4>Methods</h4>The study was a retrospective chart review w...
Guardado en:
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2014
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/ffe5b2d2639649b7a94244aa1b73384c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:ffe5b2d2639649b7a94244aa1b73384c |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:ffe5b2d2639649b7a94244aa1b73384c2021-11-18T08:27:24ZAn eight-year clinic experience with clozapine use in a Parkinson's disease clinic setting.1932-620310.1371/journal.pone.0091545https://doaj.org/article/ffe5b2d2639649b7a94244aa1b73384c2014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24646688/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>To examine our eight year clinic-based experience in a Parkinson's disease expert clinical care center using clozapine as a treatment for refractory psychosis in Parkinson's disease (PD).<h4>Methods</h4>The study was a retrospective chart review which covered eight years of clozapine registry use. Statistical T-tests, chi-square, correlations and regression analysis were used to analyze treatment response for potential associations of age, disease duration, and Hoehn & Yahr (H&Y) score, and degree of response to clozapine therapy.<h4>Results</h4>There were 36 participants included in the analysis (32 PD, 4 parkinsonism-plus). The characteristics included 30.6% female, age 45-87 years (mean 68.3±10.15), disease duration of 17-240 months (mean 108.14±51.13) and H&Y score of 2 to 4 (mean 2.51±0.51). The overall retention rate on clozapine was 41% and the most common reasons for discontinuation were frequent blood testing (28%), nursing home (NH) placement (11%) and leucopenia (8%). Responses to clozapine across the cohort were: complete (33%), partial (33%), absent (16%), and unknown (16%). Age (r = -0.36, p<0.01) and H&Y score (r = -0.41, p<0.01) were shown to be related to response to clozapine therapy, but disease duration was not an associated factor (r = 0.21, p>0.05).<h4>Conclusions</h4>This single-center experience highlights the challenges associated with clozapine therapy in PD psychosis. Frequent blood testing remains a significant barrier for clozapine, even in patients with therapeutic benefit. Surprisingly, all patients admitted to a NH discontinued clozapine due to logistical issues of administration and monitoring within that setting. Consideration of the barriers to clozapine therapy will be important to its use and to its continued success in an outpatient setting.Nawaz HackSarah M FayadErin H MonariUmer AkbarAngela HardwickRamon L RodriguezIrene A MalatyJanet RomrellAparna A Wagle ShuklaNikolaus McFarlandHerbert E WardMichael S OkunPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 3, p e91545 (2014) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Nawaz Hack Sarah M Fayad Erin H Monari Umer Akbar Angela Hardwick Ramon L Rodriguez Irene A Malaty Janet Romrell Aparna A Wagle Shukla Nikolaus McFarland Herbert E Ward Michael S Okun An eight-year clinic experience with clozapine use in a Parkinson's disease clinic setting. |
| description |
<h4>Background</h4>To examine our eight year clinic-based experience in a Parkinson's disease expert clinical care center using clozapine as a treatment for refractory psychosis in Parkinson's disease (PD).<h4>Methods</h4>The study was a retrospective chart review which covered eight years of clozapine registry use. Statistical T-tests, chi-square, correlations and regression analysis were used to analyze treatment response for potential associations of age, disease duration, and Hoehn & Yahr (H&Y) score, and degree of response to clozapine therapy.<h4>Results</h4>There were 36 participants included in the analysis (32 PD, 4 parkinsonism-plus). The characteristics included 30.6% female, age 45-87 years (mean 68.3±10.15), disease duration of 17-240 months (mean 108.14±51.13) and H&Y score of 2 to 4 (mean 2.51±0.51). The overall retention rate on clozapine was 41% and the most common reasons for discontinuation were frequent blood testing (28%), nursing home (NH) placement (11%) and leucopenia (8%). Responses to clozapine across the cohort were: complete (33%), partial (33%), absent (16%), and unknown (16%). Age (r = -0.36, p<0.01) and H&Y score (r = -0.41, p<0.01) were shown to be related to response to clozapine therapy, but disease duration was not an associated factor (r = 0.21, p>0.05).<h4>Conclusions</h4>This single-center experience highlights the challenges associated with clozapine therapy in PD psychosis. Frequent blood testing remains a significant barrier for clozapine, even in patients with therapeutic benefit. Surprisingly, all patients admitted to a NH discontinued clozapine due to logistical issues of administration and monitoring within that setting. Consideration of the barriers to clozapine therapy will be important to its use and to its continued success in an outpatient setting. |
| format |
article |
| author |
Nawaz Hack Sarah M Fayad Erin H Monari Umer Akbar Angela Hardwick Ramon L Rodriguez Irene A Malaty Janet Romrell Aparna A Wagle Shukla Nikolaus McFarland Herbert E Ward Michael S Okun |
| author_facet |
Nawaz Hack Sarah M Fayad Erin H Monari Umer Akbar Angela Hardwick Ramon L Rodriguez Irene A Malaty Janet Romrell Aparna A Wagle Shukla Nikolaus McFarland Herbert E Ward Michael S Okun |
| author_sort |
Nawaz Hack |
| title |
An eight-year clinic experience with clozapine use in a Parkinson's disease clinic setting. |
| title_short |
An eight-year clinic experience with clozapine use in a Parkinson's disease clinic setting. |
| title_full |
An eight-year clinic experience with clozapine use in a Parkinson's disease clinic setting. |
| title_fullStr |
An eight-year clinic experience with clozapine use in a Parkinson's disease clinic setting. |
| title_full_unstemmed |
An eight-year clinic experience with clozapine use in a Parkinson's disease clinic setting. |
| title_sort |
eight-year clinic experience with clozapine use in a parkinson's disease clinic setting. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2014 |
| url |
https://doaj.org/article/ffe5b2d2639649b7a94244aa1b73384c |
| work_keys_str_mv |
AT nawazhack aneightyearclinicexperiencewithclozapineuseinaparkinsonsdiseaseclinicsetting AT sarahmfayad aneightyearclinicexperiencewithclozapineuseinaparkinsonsdiseaseclinicsetting AT erinhmonari aneightyearclinicexperiencewithclozapineuseinaparkinsonsdiseaseclinicsetting AT umerakbar aneightyearclinicexperiencewithclozapineuseinaparkinsonsdiseaseclinicsetting AT angelahardwick aneightyearclinicexperiencewithclozapineuseinaparkinsonsdiseaseclinicsetting AT ramonlrodriguez aneightyearclinicexperiencewithclozapineuseinaparkinsonsdiseaseclinicsetting AT ireneamalaty aneightyearclinicexperiencewithclozapineuseinaparkinsonsdiseaseclinicsetting AT janetromrell aneightyearclinicexperiencewithclozapineuseinaparkinsonsdiseaseclinicsetting AT aparnaawagleshukla aneightyearclinicexperiencewithclozapineuseinaparkinsonsdiseaseclinicsetting AT nikolausmcfarland aneightyearclinicexperiencewithclozapineuseinaparkinsonsdiseaseclinicsetting AT herberteward aneightyearclinicexperiencewithclozapineuseinaparkinsonsdiseaseclinicsetting AT michaelsokun aneightyearclinicexperiencewithclozapineuseinaparkinsonsdiseaseclinicsetting AT nawazhack eightyearclinicexperiencewithclozapineuseinaparkinsonsdiseaseclinicsetting AT sarahmfayad eightyearclinicexperiencewithclozapineuseinaparkinsonsdiseaseclinicsetting AT erinhmonari eightyearclinicexperiencewithclozapineuseinaparkinsonsdiseaseclinicsetting AT umerakbar eightyearclinicexperiencewithclozapineuseinaparkinsonsdiseaseclinicsetting AT angelahardwick eightyearclinicexperiencewithclozapineuseinaparkinsonsdiseaseclinicsetting AT ramonlrodriguez eightyearclinicexperiencewithclozapineuseinaparkinsonsdiseaseclinicsetting AT ireneamalaty eightyearclinicexperiencewithclozapineuseinaparkinsonsdiseaseclinicsetting AT janetromrell eightyearclinicexperiencewithclozapineuseinaparkinsonsdiseaseclinicsetting AT aparnaawagleshukla eightyearclinicexperiencewithclozapineuseinaparkinsonsdiseaseclinicsetting AT nikolausmcfarland eightyearclinicexperiencewithclozapineuseinaparkinsonsdiseaseclinicsetting AT herberteward eightyearclinicexperiencewithclozapineuseinaparkinsonsdiseaseclinicsetting AT michaelsokun eightyearclinicexperiencewithclozapineuseinaparkinsonsdiseaseclinicsetting |
| _version_ |
1718421781696479232 |